{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T15:55:09Z","timestamp":1766159709981,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.dld.2025.05.005","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T15:11:27Z","timestamp":1749309087000},"page":"1630-1636","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Severe enterocolitis associated with phosphatidylinositol 3\u2010kinase delta inhibitors: A multicentre cohort study"],"prefix":"10.1016","volume":"57","author":[{"given":"Marc","family":"Howaizi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vered","family":"Abitbol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Uzzan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nassim","family":"Hammoudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3482-3331","authenticated-orcid":false,"given":"Jean-Marie","family":"Michot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Carbonnel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6676-1222","authenticated-orcid":false,"given":"Aurelien","family":"Amiot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2025.05.005_bib0001","first-page":"1759","article-title":"Drug-Induced Colitis","volume":"19","author":"Hamdeh","year":"2021","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"10.1016\/j.dld.2025.05.005_bib0002","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1136\/gutjnl-2018-316948","article-title":"Enterocolitis due to immune checkpoint inhibitors: a systematic review","volume":"67","author":"Soularue","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.dld.2025.05.005_bib0003","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/ni848","article-title":"Sustained and dynamic inositol lipid metabolism inside and outside the immunological synapse","volume":"3","author":"Costello","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.dld.2025.05.005_bib0004","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/ni847","article-title":"Imaging antigen-induced PI3K activation in T cells","volume":"3","author":"Harriague","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.dld.2025.05.005_bib0005","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1126\/science.283.5400.393","article-title":"Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha","volume":"283","author":"Fruman","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.dld.2025.05.005_bib0006","first-page":"5122","article-title":"The p110delta isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells","volume":"177","author":"Okkenhaug","year":"2006","journal-title":"J Immunol Baltim Md 1950"},{"key":"10.1016\/j.dld.2025.05.005_bib0007","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.dld.2025.05.005_bib0008","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"Herishanu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.dld.2025.05.005_bib0009","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2025.05.005_bib0010","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2025.05.005_bib0011","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","volume":"56","author":"Coutr\u00e9","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.dld.2025.05.005_bib0012","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/PAS.0000000000000525","article-title":"Idelalisib-associated enterocolitis: clinicopathologic features and distinction from other enterocolitides","volume":"39","author":"Louie","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.dld.2025.05.005_bib0013","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1097\/PAS.0000000000000522","article-title":"Idelalisib-associated Colitis: histologic Findings in 14 Patients","volume":"39","author":"Weidner","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.dld.2025.05.005_bib0014","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1053\/j.gastro.2010.07.008","article-title":"Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110\u03b4","volume":"139","author":"Uno","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2025.05.005_bib0015","first-page":"3958","article-title":"Innate PI3K p110\u03b4 regulates Th1\/Th17 development and microbiota-dependent colitis","volume":"192","author":"Steinbach","year":"2014","journal-title":"J Immunol Baltim Md 1950"},{"key":"10.1016\/j.dld.2025.05.005_bib0016","first-page":"6598","article-title":"Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells","volume":"177","author":"Patton","year":"2006","journal-title":"J Immunol Baltim Md 1950"},{"key":"10.1016\/j.dld.2025.05.005_bib0017","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.3390\/cancers15082279","article-title":"Management of Gastro-Intestinal Toxicity of the Pi3 Kinase Inhibitor: optimizing future dosing strategies","volume":"15","author":"Breal","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.dld.2025.05.005_bib0018","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/hon.2540","article-title":"Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: a multidisciplinary position paper","volume":"37","author":"Cuneo","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.dld.2025.05.005_bib0019","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/bjd.21716","article-title":"Paradoxical reactions and biologic agents: a French cohort study of 9303 patients","volume":"187","author":"Bataille","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.dld.2025.05.005_bib0020","unstructured":"codoc, Une suite d\u2019application avec entrep\u00f4t de donn\u00e9es de sant\u00e9 pour acc\u00e9l\u00e9rer la recherche. codoc n.d. https:\/\/www.codoc.co\/fr (accessed June 25, 2024)."},{"key":"10.1016\/j.dld.2025.05.005_bib0021","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE), Protocol development, CTEP n.d. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm (accessed June 24, 2024)."},{"key":"10.1016\/j.dld.2025.05.005_bib0022","unstructured":"ECOG performance status scale. ECOG-ACRIN Cancer Res Group n.d. https:\/\/ecog-acrin.org\/resources\/ecog-performance-status\/(accessed June 24, 2024)."},{"key":"10.1016\/j.dld.2025.05.005_bib0023","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2025.05.005_bib0024","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.kint.2020.04.020","article-title":"Controversies in acute kidney injury: conclusions from a Kidney Disease: improving Global Outcomes (KDIGO) Conference","volume":"98","author":"Ostermann","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.dld.2025.05.005_bib0025","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/gutjnl-2011-300486","article-title":"Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)","volume":"61","author":"Travis","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.dld.2025.05.005_bib0026","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.2217\/fon-2017-0528","article-title":"Pathological assessment of gastrointestinal biopsies from patients with idelalisib-associated diarrhea and colitis","volume":"14","author":"Yeung","year":"2018","journal-title":"Future Oncol Lond Engl"},{"key":"10.1016\/j.dld.2025.05.005_bib0027","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.dld.2025.05.005_bib0028","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/bjh.17145","article-title":"Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study","volume":"193","author":"Marchesini","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.dld.2025.05.005_bib0029","article-title":"Therapeutic agents affecting the immune system and drug-induced inflammatory bowel disease (IBD): a review on etiological and pathogenetic aspects","volume":"234","author":"Del Sordo","year":"2022","journal-title":"Clin Immunol Orlando Fla"},{"key":"10.1016\/j.dld.2025.05.005_bib0030","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.17475","article-title":"A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel)","volume":"194","author":"Eyre","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.dld.2025.05.005_bib0031","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/hon.2861","article-title":"Efficacy of idelalisib and rituximab in relapsed\/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group","volume":"39","author":"Rigolin","year":"2021","journal-title":"Hematol Oncol"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865825007789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865825007789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T03:55:57Z","timestamp":1760154957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865825007789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1590865825007789"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2025.05.005","relation":{},"ISSN":["1590-8658"],"issn-type":[{"type":"print","value":"1590-8658"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe enterocolitis associated with phosphatidylinositol 3\u2010kinase delta inhibitors: A multicentre cohort study","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2025.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}